Industry Asks CMS Not To Tread On FDA's Medtech Safety Authority
This article was originally published in The Gray Sheet
Executive Summary
CMS should leave questions regarding medtech safety to FDA rather than re-examine them in coverage with evidence development studies, according to physicians and industry stakeholders.